Anrukinzumab: Difference between revisions
No edit summary Tag: Manual revert |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|Monoclonal antibody for the treatment of asthma}} | |||
{{Drugbox | {{Drugbox | ||
| | | verifiedfields = changed | ||
| | | verifiedrevid = 477241703 | ||
| | | image = <!-- Image of the drug --> | ||
| image_size = 250px | |||
| image_alt = | |||
| image_caption = | |||
| type = mab | | type = mab | ||
| mab_type = mab | | mab_type = mab | ||
| | | mab_target = IL-13 | ||
| legal_status = | | legal_status = | ||
| routes_of_administration = | | routes_of_administration = | ||
| | | cas_number = 946415-98-3 | ||
| chemspiderid = | |||
| atc_prefix = none | |||
| drugbank = | |||
| kegg = | |||
| synonyms = | |||
| | |||
| | |||
| | |||
| | |||
}} | }} | ||
'''Anrukinzumab''' | '''Anrukinzumab''' is a [[monoclonal antibody]] that was developed for the treatment of [[asthma]]. It is a humanized antibody that targets the [[interleukin-13]] (IL-13) cytokine, which plays a key role in the inflammatory process associated with asthma. | ||
Anrukinzumab | ==Mechanism of Action== | ||
Anrukinzumab works by binding to IL-13, a cytokine involved in the [[immune system]]'s response to allergens. IL-13 is known to contribute to the pathophysiology of asthma by promoting [[inflammation]], [[mucus]] production, and airway hyperresponsiveness. By inhibiting IL-13, anrukinzumab reduces these effects, potentially alleviating symptoms in patients with asthma. | |||
== | ==Development and Clinical Trials== | ||
Anrukinzumab was initially developed by [[MedImmune]], a subsidiary of [[AstraZeneca]]. The drug underwent several [[clinical trials]] to evaluate its safety and efficacy in treating asthma. However, the development of anrukinzumab was eventually discontinued. | |||
During its clinical evaluation, anrukinzumab was administered to patients with moderate to severe asthma to assess its impact on lung function and asthma control. The trials aimed to determine the optimal dosing regimen and to identify any potential side effects associated with the treatment. | |||
==Potential Applications== | |||
While anrukinzumab was primarily investigated for asthma, the mechanism of targeting IL-13 suggests potential applications in other [[allergic]] and [[inflammatory diseases]]. IL-13 is implicated in conditions such as [[atopic dermatitis]] and [[chronic rhinosinusitis]] with nasal polyps, making it a target of interest for various therapeutic interventions. | |||
==Discontinuation== | |||
Despite the promising mechanism of action, the development of anrukinzumab was halted. The reasons for discontinuation could include insufficient efficacy in clinical trials, safety concerns, or strategic business decisions by the developing company. | |||
==Related pages== | |||
* [[Monoclonal antibody therapy]] | |||
* [[Asthma]] | |||
* [[Interleukin-13]] | |||
* [[MedImmune]] | |||
[[Category:Monoclonal antibodies]] | |||
[[Category:Asthma treatments]] | |||
[[Category:Immunology]] | |||
Latest revision as of 19:12, 22 March 2025
Monoclonal antibody for the treatment of asthma
| Anrukinzumab | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Anrukinzumab is a monoclonal antibody that was developed for the treatment of asthma. It is a humanized antibody that targets the interleukin-13 (IL-13) cytokine, which plays a key role in the inflammatory process associated with asthma.
Mechanism of Action[edit]
Anrukinzumab works by binding to IL-13, a cytokine involved in the immune system's response to allergens. IL-13 is known to contribute to the pathophysiology of asthma by promoting inflammation, mucus production, and airway hyperresponsiveness. By inhibiting IL-13, anrukinzumab reduces these effects, potentially alleviating symptoms in patients with asthma.
Development and Clinical Trials[edit]
Anrukinzumab was initially developed by MedImmune, a subsidiary of AstraZeneca. The drug underwent several clinical trials to evaluate its safety and efficacy in treating asthma. However, the development of anrukinzumab was eventually discontinued.
During its clinical evaluation, anrukinzumab was administered to patients with moderate to severe asthma to assess its impact on lung function and asthma control. The trials aimed to determine the optimal dosing regimen and to identify any potential side effects associated with the treatment.
Potential Applications[edit]
While anrukinzumab was primarily investigated for asthma, the mechanism of targeting IL-13 suggests potential applications in other allergic and inflammatory diseases. IL-13 is implicated in conditions such as atopic dermatitis and chronic rhinosinusitis with nasal polyps, making it a target of interest for various therapeutic interventions.
Discontinuation[edit]
Despite the promising mechanism of action, the development of anrukinzumab was halted. The reasons for discontinuation could include insufficient efficacy in clinical trials, safety concerns, or strategic business decisions by the developing company.
